This paper on early treatment was the key paper with the treatment algorithm; I wrote with Dr. McCullough & is listed as 2nd author. But you see who is the last author, Zev, he was senior scientist

by Paul Alexander

We had Zev as last author as he was the senior scientist with guidance. It was his work we developed and formulated. He is and was transformational. This tells you his role in early treatment

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)

Peter A McCullough 1Paul E Alexander 2Robin Armstrong 3Cristian Arvinte 4Alan F Bain 5Richard P Bartlett 6Robert L Berkowitz 7Andrew C Berry 8Thomas J Borody 9Joseph H Brewer 10Adam M Brufsky 11Teryn Clarke 12Roland Derwand 13Alieta Eck 14John Eck 14Richard A Eisner 15George C Fareed 16Angelina Farella 17Silvia N S Fonseca 18Charles E Geyer Jr 19Russell S Gonnering 20Karladine E Graves 21Kenneth B V Gross 22Sabine Hazan 23Kristin S Held 24H Thomas Hight 25Stella Immanuel 26Michael M Jacobs 27Joseph A Ladapo 28Lionel H Lee 29John Littell 30Ivette Lozano 31Harpal S Mangat 32Ben Marble 33John E McKinnon 34Lee D Merritt 35Jane M Orient 36Ramin Oskoui 37Donald C Pompan 38Brian C Procter 39Chad Prodromos 40Juliana Cepelowicz Rajter 41Jean-Jacques Rajter 41C Venkata S Ram 42Salete S Rios 43Harvey A Risch 44Michael J A Robb 45Molly Rutherford 46Martin Scholz 47Marilyn M Singleton 48James A Tumlin 49Brian M Tyson 50Richard G Urso 51Kelly Victory 52Elizabeth Lee Vliet 53Craig M Wax 54Alexandre G Wolkoff 55Vicki Wooll 56Vladimir Zelenko 57

Affiliations expand

Free article


The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death. Prompt early initiation of sequenced multidrug therapy (SMDT) is a widely and currently available solution to stem the tide of hospitalizations and death. A multipronged therapeutic approach includes 1) adjuvant nutraceuticals, 2) combination intracellular anti-infective therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet agents/anticoagulants, 5) supportive care including supplemental oxygen, monitoring, and telemedicine. Randomized trials of individual, novel oral therapies have not delivered tools for physicians to combat the pandemic in practice. No single therapeutic option thus far has been entirely effective and therefore a combination is required at this time. An urgent immediate pivot from single drug to SMDT regimens should be employed as a critical strategy to deal with the large numbers of acute COVID-19 patients with the aim of reducing the intensity and duration of symptoms and avoiding hospitalization and death.

Keywords: COVID-19; SARS-CoV-2; ambulatory treatment; anti-infective; anti-inflammatory; anticoagulant; antiplatelet agent; antiviral; corticosteroid; hospitalization; mortality; sequenced multidrug therapy.